Investors reacted strongly when the Centers for Medicare & Medicaid Services unveiled a proposed average rate increase of just 0.09% for 2027, well below the 4–6% gains anticipated by market participants. CVS Health’s shares tumbled by approximately 14% on the news, underperforming broader retail pharmacy peers and reflecting concerns that flat Medicare Advantage reimbursement growth will compress pharmacy and health benefits margins over the next fiscal year.

Bank of America reduced its 12-month price target from 100 to 95 while maintaining a Buy rating, signaling continued confidence in CVS Health’s long-term upside. Outperform and Overweight ratings from Evercore ISI, TD Cowen and Barclays with target ranges between 93 and 105 underscore a moderate buy consensus. Of 24 analysts tracked, 20 recommend buying the shares and four are at Hold, resulting in an average target near 95 and a moderate buy consensus from the sell side.

In its latest quarter, CVS Health delivered revenue of 102.9 billion on a year-over-year gain of 7.8% and reported earnings per share of 1.60, exceeding consensus by 0.24. Management set fiscal 2025 adjusted EPS guidance between 6.55 and 6.65, reflecting confidence in core pharmacy and clinical services growth despite headwinds from low Medicare Advantage rates. These fundamental beats helped underpin investor belief in the company’s ability to sustain mid-single-digit profit growth.

Major asset managers continue to hold sizable positions: Vanguard boosted its stake to 120.4 million shares, Capital World Investors owns 68.4 million shares, and State Street holds 58.9 million, collectively representing over 80% institutional ownership. CVS Health declared a quarterly dividend of 0.665, translating into a 3.7% yield and annualized payout of 2.66. A small insider purchase of 24 shares at approximately 53.70 per share by an executive offers a symbolic sign of management confidence in the company’s valuation.